Since TREM2 is a potential therapeutic target for AD, the pharmaceutical industry has initiated several projects aimed at developing TREM2 antibody therapeutics, with at least two candidates having commenced clinical trials. This evidence concerns the gene TREM2 and Alzheimer disease.